Trial · NCT00006721
Results by group310
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 310
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival at 2 Years | CHOP + Rituximab | 76 | percentage of participants | ||
| Progression-free Survival at 2 Years | CHOP + Tositumomab | 80 | percentage of participants | ||
| Objective Response (Confirmed and Unconfirmed Complete and Partial Responses) | CHOP + Rituximab | 224 | participants | ||
| Objective Response (Confirmed and Unconfirmed Complete and Partial Responses) | CHOP + Tositumomab | 223 | participants | ||
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP Only | ARDS | 0 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP + Rituximab | ARDS | 0 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP + Tositumomab | ARDS | 1 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP Only | Abdominal pain/cramping | 0 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP + Rituximab | Abdominal pain/cramping | 4 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP + Tositumomab | Abdominal pain/cramping | 3 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP Only | Allergic reaction | 0 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP + Rituximab | Allergic reaction | 9 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP + Tositumomab | Allergic reaction | 1 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP Only | Anemia | 0 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP + Rituximab | Anemia | 7 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP + Tositumomab | Anemia | 8 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP Only | Anorexia | 0 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP + Rituximab | Anorexia | 3 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP + Tositumomab | Anorexia | 2 | Participants | |
| Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug | CHOP Only | Anxiety/agitation | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00006721/results